RxDoctor Payments Data

Jennie Law, MD

Hematology & Oncology · Baltimore, MDNPI 1225296692

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,850 of the $3,974 with a category attached, or 96.9%. Merck accounts for 97.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $929 and has fallen 56.9% since, to $401 in 2025.

$3,974in general payments, 2019–2025

Across 14 payments — averaging $283.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$4K
  • AbbVie$54
  • Pharmacyclics LLC, An Abbvie Company$22
  • Amgen$22
$1,187,516in research payments, 2019–2025

Across 125 payments — averaging $9500.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$324K
  • Global Blood Therapeutics, Inc.$218K
  • AbbVie$200K
  • Beigene, Ltd.$127K
  • Novartis$106K
  • Incyte Corporation$69K
  • plus $142K from 7 others

What the payments were for

  • Consulting fees$3,85097%
  • Food & beverage$982%
  • Education$261%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck10$3,876
AbbVie2$54
Pharmacyclics LLC, An Abbvie Company1$22
Amgen1$22

How this compares

$3,974 in reported general payments places this provider in the 60th percentile of 242 hematology & oncology providers in Maryland.

See all hematology & oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$50,338
Medicare patients
148
Services billed
437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate45$633,440
ImbruvicaIbrutinib14$247,893
OxbrytaVoxelotor20$243,399
Deferasirox17$92,169
EliquisApixaban18$22,711
Fentanyl12$3,290
Acyclovir31$915
Oxycodone Hcl66$895
Hydroxyurea33$783
Morphine Sulfate ErMorphine Sulfate28$440
Ondansetron OdtOndansetron13$411
Hydromorphone Hcl31$294
Ondansetron Hcl12$114
Prednisone27$48
Cyclobenzaprine Hcl13$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$22$247,89314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 242 hematology & oncology providers in Maryland.

Other hematology & oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →